Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 4/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.41 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | KLK7 | P49862 | 2/20 | 0.40 |
| ▸ | EHD1 | Q9H4M9 | 1/20 | 0.40 |
| ▸ | F12 | P00748 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.38 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 2/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113585 | 0.78 | PLAU (0.51) | AVPR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13038608 | 0.75 | MC4R (0.51) | TSLP | |
| SCHEMBL13881404 | 0.75 | MC4R (0.51) | TSLP | |
| SCHEMBL13113566 | 0.74 | SSTR2 (0.50) | AVPR1ATBXA2RPDE4DPDE3ASSTR1 | |
| SCHEMBL16349705 | 0.74 | SSTR2 (0.47) | AVPR1ATBXA2RPDE4DPDE3ASSTR1 | |
| SCHEMBL16349623 | 0.74 | PLAU (0.46) | AVPR1ATBXA2RPDE4DPDE3ASSTR1 | |
| SCHEMBL13287941 | 0.74 | SSTR2 (0.50) | AVPR1ATBXA2RPDE4DPDE3ASSTR1 | |
| SCHEMBL14047518 | 0.73 | PLAU (0.38) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12082795 | 0.73 | IL23R (0.52) | AVPR1ATBXA2RPDE4DPDE3ASSTR1 | |
| SCHEMBL13113570 | 0.72 | SSTR2 (0.44) | AVPR1ATBXA2RPDE4DPDE3ASSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | CD44, CD47, EPCAM | AVPR1A 3643/4885TBXA2R 2178/4885PDE4D 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.